BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/15/2016 3:38:00 PM | Browse: 488 | Download: 384
Publication Name World Journal of Gastroenterology
Manuscript ID 25695
Country/Territory Italy
2016-03-21 09:23
Peer-Review Started
2016-03-22 16:18
To Make the First Decision
2016-04-14 11:14
Return for Revision
2016-04-17 17:47
2016-05-09 23:41
Second Decision
2016-06-06 08:14
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2016-06-15 17:48
Articles in Press
2016-06-15 17:49
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2016-07-07 10:22
Publish the Manuscript Online
2016-07-15 15:38
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Topic Highlights
Article Title Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?
Manuscript Source Invited Manuscript
All Author List Liliana Montella, Giovannella Palmieri, Raffaele Addeo and Salvatore Del Prete
Funding Agency and Grant Number
Corresponding author Liliana Montella, MD, Medical Oncology Unit, “San Giovanni di Dio” Hospital, via D.Pirozzi 66, Frattamaggiore, 80027 Naples, Italy. lilianamontella@libero.it
Keywords Hepatocellular carcinoma; Targeted therapy; Pathway; Angiogenesis; Sorafenib
Core Tip Hepatocellular carcinoma (HCC) is a tumor with increasing incidence and epidemiologic relevance. Advanced hepatocellular carcinoma that is not amenable to radical treatments (i.e., transplantation or surgical resection) has a dismal prognosis (1-2 mo). Sorafenib, a tyrosine kinase inhibitor which targets multiple pro-angiogenic factors, is a cornerstone in the history of HCC treatments. Since the introduction of sorafenib, novel biological drugs have been investigated in hepatocellular carcinoma patients, but no monotherapy or combination therapy has significantly improved outcomes in clinical trials. Insights into tumor gene profile are critical in recognizing various classes of hepatocellular carcinoma in order to help determine which therapeutic approaches will be beneficial. Well-designed clinical trials may disclose differences in efficacy end-points, thus leading the way to clinical use.
Publish Date 2016-07-15 15:38
Citation Montella L, Palmieri G, Addeo R, Del Prete S. Hepatocellular carcinoma: will novel targeted drugs really impact the next future? World J Gastroenterol 2016; 22(27): 6114-6126
Url http://www.wjgnet.com/1007-9327/full/v22/i27/6114.htm
DOI http://dx.doi.org/10.3748/wjg.v22.i27.6114
Full Article (PDF) WJG-22-6114.pdf
Full Article (Word) WJG-22-6114.doc
Manuscript File 25695-Review.docx
Answering Reviewers 25695-Answering reviewers.pdf
Audio Core Tip 25695-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 25695-Conflict-of-interest statement.pdf
Copyright License Agreement 25695-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 25695-Language certificate.pdf
Peer-review Report 25695-Peer-review(s).pdf
Scientific Misconduct Check 25695-Scientific misconduct check.pdf
Scientific Editor Work List 25695-Scientific editor work list.pdf